Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market By Drug Class (Targeted Disease-Modifying Therapies, Non-Steroidal Anti-Inflammatory Drugs [NSAIDs] & COX-2 Inhibitors, Corticosteroids, Bisphosphonates); By Treatment Type (Medication, Occupational & Gentle Physical Therapy, Surgery [Exceptional/Emergency Procedures]); By Route of Administration (Oral Administration, Parenteral/Intravenous Administration, Topical Administration); By End User & Distribution Channel (Specialty, Retail & Online Pharmacies, Hospitals & Specialty Clinics); By Geography (North America, Asia-Pacific, Europe, Middle East & Africa, Latin America), Segment Revenue Estimation, Forecast, 2026–2032

How Are New Drug Approvals, Targeted Therapies, and Expanding Treatment Access Driving Growth in the Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market?

The Global Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market was valued at USD 27.8 million in 2025 and is projected to reach USD 172.0 million by 2032, expanding at a CAGR of 29.7% during 2026–2032, according to Strategic Market Research. FOP is an extremely rare genetic disorder that causes abnormal bone formation in muscles and connective tissues, progressively restricting mobility. Market growth is increasingly influenced by the introduction of targeted medicines, improved diagnosis, and expanding access to specialized treatment.

 

The small but underserved patient population creates opportunities for rare disease therapies. Approximately 400 people in the United States are estimated to be living with FOP, while the International FOP Association recognizes around 900 confirmed cases globally. Population-based estimates suggest that 2,600–4,000 people worldwide may have the condition, highlighting potential underdiagnosis and the importance of specialist referral networks in expanding treatment access.

 

New FDA approvals are expanding the commercial potential of disease-modifying treatments. As of October 2026, the United States has three FDA-approved FOP medicines: Sohonos, approved in August 2023; Pasatru, approved in August 2026; and Atebrioz, approved in September 2026. The availability of treatments for different eligible age groups is creating opportunities for pharmaceutical manufacturers while increasing the importance of specialist care, insurance coverage, and long-term treatment access.

 

The market is shifting from supportive care toward targeted pharmaceutical treatment. Corticosteroids, pain management, and specialized rehabilitation remain important for managing symptoms, while approved therapies address abnormal bone formation and, for certain treatments, disease flare-ups. Future market expansion will depend on earlier diagnosis, treatment eligibility, patient access, and successful commercialization of newly approved medicines.

 

Which FOP Treatment Segments Lead Market Revenue and Offer the Fastest Growth Opportunities?

By Drug Class: Targeted Therapies Lead the Shift Toward Disease Modification

Leading and Fastest-Growing Subsegment – Targeted Disease-Modifying Therapies

Targeted disease-modifying therapies lead the Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market, accounting for an estimated 84.5% market share, valued at USD 23.49 million in 2025, and are projected to register the fastest CAGR of 32.23% during 2026–2032. Treatments targeting abnormal molecular signaling pathways, particularly ACVR1-related signaling, aim to reduce the formation of unwanted bone in muscles and connective tissues. The shift from symptom management toward targeted therapeutic intervention is expanding treatment opportunities and encouraging pharmaceutical investment in rare genetic disorders.

 

By Treatment Type: Medication Drives the Transition to Targeted FOP Care

Leading and Fastest-Growing Subsegment – Medication

Medication dominates the global Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market, accounting for approximately 96% market share, valued at USD 26.69 million in 2025, and is projected to register the fastest CAGR of 30.31% during 2026–2032. Pharmacological treatments play a central role in managing abnormal bone formation, painful flare-ups, and progressive mobility loss associated with FOP. The introduction of targeted medicines, including palovarotene, has expanded treatment options beyond corticosteroids and anti-inflammatory drugs, allowing eligible patients to receive therapies aimed at reducing new bone formation.

 

By Route of Administration: Oral Treatment Leads as Intravenous Therapies Accelerate

Leading Subsegment – Oral Administration

Oral administration dominates the Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market, accounting for an estimated 90% market share, valued at USD 25.02 million in 2025, and is projected to expand at a CAGR of 26.16% during 2026–2032. Oral therapies play a crucial role in FOP management because intramuscular injections can trigger painful flare-ups and irreversible abnormal bone formation. The availability of oral treatments, including palovarotene, provides patients with a less invasive therapeutic option while supporting long-term disease management and treatment continuity.

Fastest-Growing Subsegment – Parenteral/Intravenous Administration

Parenteral and intravenous administration holds an estimated 5% share of the Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market, valued at USD 1.39 million in 2025, and is projected to record the fastest CAGR of 63.06% during 2026–2032. Intravenous administration has a highly restricted role in FOP management because invasive procedures can trigger flare-ups and abnormal bone formation. Its clinical use remains limited to carefully supervised interventions for severe complications, where specialized medical care and controlled administration are essential to patient safety and treatment outcomes.

 

By End User and Distribution Channel: Specialty Pharmacies Anchor Access as Clinical Treatment Expands

Leading Subsegment – Specialty, Retail, and Online Pharmacies

Specialty, retail, and online pharmacies dominate the Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market, accounting for an estimated 80% market share, valued at USD 22.24 million in 2025, and are projected to expand at a CAGR of 25.98% during 2026–2032. Specialty pharmacies manage complex orphan medications, including targeted FOP therapies requiring coordinated distribution and patient support. Retail pharmacies provide supportive medications for pain management and flare-ups, while online pharmacies facilitate prescription refills and home delivery, improving treatment accessibility and continuity for patients with restricted mobility.

Fastest-Growing Subsegment – Hospitals and Specialty Clinics

Hospitals and specialty clinics represent an estimated 20% share of the Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market, accounting for USD 5.56 million in 2025, and are projected to register the fastest CAGR of 40.47% during 2026–2032. Specialized treatment centers provide coordinated multidisciplinary care involving geneticists, orthopedic specialists, rehabilitation professionals, and pain management teams. Their role in early diagnosis, managing abnormal bone formation, administering targeted therapies, and monitoring disease progression is expanding access to specialized FOP treatment and long-term patient care.

 

By Geography: North America Leads Commercialization While Asia-Pacific Accelerates Access

Leading Region – North America

North America leads the Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market with an estimated 80% market share, valued at USD 22.24 million in 2025, and is projected to grow at a CAGR of 29.79% during 2026–2032. The region is witnessing a major transition from supportive care toward targeted disease-modifying therapies that address abnormal bone formation. The United States remains the primary contributor, supported by FDA approval of Sohonos (palovarotene), specialized rare disease treatment centers, improved diagnosis, and expanding access to FOP-specific medications.

Fastest-Growing Region – Asia-Pacific

Asia-Pacific accounted for an estimated 8% share of the global Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market, valued at USD 2.22 million in 2025, and is projected to register the fastest regional CAGR of 33.72% during 2026–2032. Growing awareness of rare genetic disorders, improvements in early FOP diagnosis, and regulatory progress toward disease-modifying therapies are expanding treatment access across the region. Japan’s regulatory advancements and increasing specialist care capabilities in China and Australia are creating opportunities for targeted FOP medications and long-term patient management.

 

Which Pharmaceutical Companies Are Leading Innovation and Commercial Growth in the FOP Treatment Market?

Ipsen – Established Commercial Leader in Disease-Modifying FOP Treatment

Ipsen holds an established commercial position through Sohonos (palovarotene), the first FDA-approved disease-modifying treatment for FOP, authorized in August 2023. According to Ipsen's financial reporting, Sohonos generated EUR 20.7 million in global sales during 2025, compared with EUR 20.8 million in 2024. The medicine represented approximately 5.4% of Ipsen's EUR 384.3 million rare-disease sales in 2025.

Sohonos reduces new heterotopic bone formation in eligible adults and children, providing a pharmaceutical option for managing disease progression. Ipsen's commercial position is supported by established specialty medicine distribution, rare-disease expertise, and regulatory approvals in several countries. Its future competitiveness will depend on patient retention, reimbursement coverage, geographical expansion, and differentiation against newly approved therapies.

Regeneron Pharmaceuticals – Leading Innovator in Targeted Antibody Treatment

Regeneron Pharmaceuticals has strengthened its position in the FOP Treatment Market through Pasatru (garetosmab), which received FDA approval on August 19, 2026, for adults with FOP. The treatment targets activin A, a protein involved in abnormal bone formation, establishing an alternative therapeutic approach to oral medicines.

In the Phase 3 OPTIMA clinical trial involving 63 patients, garetosmab achieved approximately 90%–94% reductions in new heterotopic ossification lesions over 56 weeks, depending on the administered dose, compared with placebo. The treatment also reduced clinician-assessed flare-ups. These results position Regeneron as an important competitor in disease-modifying FOP treatment, particularly within the intravenous biologics category. Its commercial opportunity depends on treatment adoption, specialist infusion access, reimbursement, and potential expansion into additional patient populations. FOP-specific commercial sales were not yet established in the 2025 market year.

Other Companies Contributing to FOP Treatment Development:

• Mirum Pharmaceuticals – Holds worldwide commercialization rights to Atebrioz (zilurgisertib), approved by the FDA in September 2026 for FOP patients aged 12 years and older, with a U.S. launch planned for October 2026.

• Incyte – Developed zilurgisertib, an oral ALK2 inhibitor, and licensed worldwide development and commercialization rights to Mirum under an agreement involving a USD 16 million upfront payment, milestone payments, and royalties.

• ashibio – Is advancing andecaliximab, an investigational anti-MMP9 antibody, through the Phase 2/3 ANDECAL clinical trial to evaluate its potential to prevent new abnormal bone formation in FOP patients.

 

Analyst Commentary

The Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market is shifting from symptom management toward targeted therapies that reduce abnormal bone formation. The strongest commercial opportunities are emerging from the introduction of newly approved medicines, expanded treatment eligibility, and improved diagnosis of previously unidentified patients. Ipsen, Regeneron, and Mirum Pharmaceuticals are shaping competition through differentiated treatment approaches. Future revenue growth will depend on patient access, specialty drug reimbursement, wider regulatory approvals, and sustained adoption of disease-modifying therapies.

 

Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 27.8 Million
Revenue Forecast in 2032	USD 172.0 Million
Overall Growth Rate	CAGR of 29.7% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Drug Class, By Treatment Type, By Route of Administration, By End User & Distribution Channel, By Geography
By Drug Class	Targeted Disease-Modifying Therapies, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and COX-2 Inhibitors, Corticosteroids, Bisphosphonates
By Treatment Type	Medication, Occupational and Gentle Physical Therapy, Surgery
By Route of Administration	Oral Administration, Parenteral/Intravenous Administration, Topical Administration
By End User & Distribution Channel	Specialty, Retail, and Online Pharmacies, Hospitals and Specialty Clinics
By Region	North America, Asia-Pacific, Europe, Middle East & Africa, Latin America
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	FDA approvals of disease-modifying FOP therapies, growing adoption of targeted treatments, expansion of treatment eligibility, increasing diagnosis of rare FOP cases, development of ACVR1/activin A pathway therapies, growing specialty-care access, expansion of oral and intravenous treatment options, and increasing investment in rare-disease drug development
Customization Option	Available upon request